CAMD评分在接受抗病毒治疗的慢性乙型肝炎患者中的验证
本研究在韩国4家教学医院3277例接受恩替卡韦或替诺福韦一线治疗的慢性HBV感染患者中验证CAMD评分预测肝细胞癌(HCC)风险的能力,并与PAGE-B、mPAGE-B比较;中位随访58.2个月,8.9%发生HCC,CAMD的iAUC为0.790,高于mPAGE-B的0.769和PAGE-B的0.760,且低、中、高CAMD评分组5年累积HCC风险分别为1.3%、8.0%、24.3%。
要点
- CAMD评分可识别接受恩替卡韦或替诺福韦治疗的慢性HBV患者中HCC高风险者。
- CAMD的iAUC为0.790,高于mPAGE-B的0.769和PAGE-B的0.760。
- 低(<8)、中(8-13)、高(>13)CAMD评分组5年累积HCC风险分别为1.3%、8.0%、24.3%。
核心结论
- CAMD评分在韩国接受恩替卡韦或替诺福韦治疗的慢性HBV感染队列中可验证用于HCC风险判断。
研究设计与样本
- 在韩国4家学术教学医院随访3277例慢性HBV感染患者(平均年龄48.7岁,男性62.6%,肝硬化32.4%),一线抗病毒药为恩替卡韦(n=1725)或替诺福韦(n=1552)。
主要发现
- 中位随访58.2个月期间,8.9%的患者发生HCC。
- 发生HCC者较未发生者年龄更大、男性比例更高、肝硬化和糖尿病比例更高(均P < .05)。
- CAMD评分识别HCC的iAUC为0.790,mPAGE-B为0.769,PAGE-B为0.760。
- 低CAMD评分(<8)组5年累积HCC风险为1.3%,中评分(8-13)组为8.0%,高评分(>13)组为24.3%(低 vs 中、中 vs 高比较P < .001)。
- HCC预测概率与观察概率具有极好的一致性。
关键数值与推荐
- CAMD评分基于肝硬化、年龄、男性、糖尿病四项。
- CAMD评分分层:低<8、中8-13、高>13。
- CAMD的iAUC 0.790;mPAGE-B的iAUC 0.769;PAGE-B的iAUC 0.760。
局限性
- 验证在韩国队列中进行,其中大多数患者为基因型C2 HBV感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Researchers previously developed a scoring system to determine the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection, based on the presence of cirrhosis, patient age, male sex, and diabetes (called the CAMD scoring system). We validated the CAMD scoring system and compared its performance with that of other risk assessment models in an independent cohort. METHODS: We followed up 3277 patients with chronic HBV infection (mean age, 48.7 y; 62.6% male; 32.4% with cirrhosis) who were treated with entecavir (n = 1725) or tenofovir (n = 1552) as the first-line antiviral agent in 4 academic teaching hospitals in the Republic of Korea. The primary outcome was development of HCC. We evaluated the ability of the CAMD, PAGE-B, and mPAGE-B scoring systems to identify patients who would develop HCC using integrated area under the curve (iAUC) analysis. RESULTS: Over a median follow-up period of 58.2 months, 8.9% of the patients developed HCC. Patients who developed HCC were older, more likely to be male, and had higher proportions of cirrhosis and diabetes than patients who did not develop HCC (all P < .05). CAMD scores identified patients who developed HCC with an iAUC of 0.790, mPAGE-B scores with an iAUC of 0.769, and PAGE-B scores with an iAUC of 0.760. The 5-year cumulative risks of HCC were 1.3% in patients with low CAMD scores (<8), 8.0% in patients with intermediate CAMD scores (8-13), and 24.3% in patients with high CAMD scores (>13) (P < .001 for comparison of low- vs intermediate-score groups and between intermediate- vs high-score groups). The predicted and observed probabilities of HCC had excellent agreement. CONCLUSIONS: We validated the CAMD scoring system in determining the risk of HCC in patients with chronic HBV treatment receiving entecavir or tenofovir treatment. Validation was performed in a cohort of patients in the Republic of Korea, where most patients have genotype C2 HBV infection.
引用
- Kim SU, Seo YS, Lee HA, et al. Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. Clin Gastroenterol Hepatol. 2019. PMID: 31252188. doi:10.1016/j.cgh.2019.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。